TY - JOUR
T1 - Pharmacotherapy of Obesity
T2 - Clinical Trials to Clinical Practice
AU - Gadde, Kishore M.
AU - Pritham Raj, Y.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Purpose of Review: This review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies—lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide 3.0 mg—which have been approved by the US Food and Drug Administration (FDA) for long-term management of obesity since 2012. Topics discussed in this paper include rationale for pharmacotherapy, history of antiobesity drugs, and efficacy and safety data from randomized controlled trials with implications for clinical practice. Recent Findings: Weight loss achieved by currently approved drugs ranges from approximately 3 to 9%, above and beyond weight loss with lifestyle counseling alone, after a year. Response and attrition rates in clinical trials indicate that the benefits of pharmacotherapy range from substantial for some patients, modest for others, and no benefits for others still. Summary: Decisions regarding selection of a suitable drug from the available pharmacotherapy options and duration of treatment should be based on the expected and observed benefit-to-risk balance and tailored to the needs of each individual patient using the principles of shared decision-making.
AB - Purpose of Review: This review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies—lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide 3.0 mg—which have been approved by the US Food and Drug Administration (FDA) for long-term management of obesity since 2012. Topics discussed in this paper include rationale for pharmacotherapy, history of antiobesity drugs, and efficacy and safety data from randomized controlled trials with implications for clinical practice. Recent Findings: Weight loss achieved by currently approved drugs ranges from approximately 3 to 9%, above and beyond weight loss with lifestyle counseling alone, after a year. Response and attrition rates in clinical trials indicate that the benefits of pharmacotherapy range from substantial for some patients, modest for others, and no benefits for others still. Summary: Decisions regarding selection of a suitable drug from the available pharmacotherapy options and duration of treatment should be based on the expected and observed benefit-to-risk balance and tailored to the needs of each individual patient using the principles of shared decision-making.
KW - Antiobesity drugs
KW - Obesity
KW - Overweight
KW - Pharmacologic treatment
KW - Pharmacotherapy
KW - Weight loss medications
UR - http://www.scopus.com/inward/record.url?scp=85017189919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017189919&partnerID=8YFLogxK
U2 - 10.1007/s11892-017-0859-2
DO - 10.1007/s11892-017-0859-2
M3 - Review article
C2 - 28378293
AN - SCOPUS:85017189919
SN - 1534-4827
VL - 17
JO - Current diabetes reports
JF - Current diabetes reports
IS - 5
M1 - 34
ER -